Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 14/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 14/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 13/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CFTR | P13569 | 1/20 | 1.00 |
| ▸ | PRKDC | P78527 | 4/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.78 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.78 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.78 |
| ▸ | PDE5A | O76074 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30917246 | 1.00 | CYP1A1 (1.00) | CYP1A1CYP1B1CYP1A2POLBCFTR | |
| Alpha-Naphthoflavone SCHEMBL29351090 | 0.88 | CYP1A1 (1.00) | CYP1A1CYP1B1CYP1A2POLBCFTR | |
| Alpha-Naphthoflavone SCHEMBL121594 | 0.88 | CYP1A1 (1.00) | CYP1A1CYP1B1CYP1A2POLBCFTR | |
| SCHEMBL31061509 | 0.85 | CYP1A1 (1.00) | CYP1A1CYP1B1CYP1A2POLBCFTR | |
| SCHEMBL20594586 | 0.83 | CYP1A1 (0.78) | CYP1A1CYP1B1CYP1A2POLBCFTR | |
| SCHEMBL29407618 | 0.83 | CYP1A1 (0.78) | CYP1A1CYP1B1CYP1A2POLBCFTR | |
| SCHEMBL31061133 | 0.83 | PRKDC (1.00) | CYP1A1CYP1B1CYP1A2POLBCFTR | |
| Alpha-Naphthoflavone SCHEMBL17292887 | 0.81 | CYP1A1 (0.84) | CYP1A1CYP1B1CYP1A2POLBCFTR | |
| SCHEMBL4650874 | 0.80 | CYP1A1 (1.00) | CYP1A1CYP1B1CYP1A2POLBCFTR | |
| Alpha-Naphthoflavone SCHEMBL3665037 | 0.80 | CYP1A1 (0.82) | CYP1A1CYP1B1CYP1A2POLBCFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206198-A1 | CFTR CHANNEL ACTIVATOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF GLUTEN SENSITIVITY CONDITIONS | MAIURI LUIGI (IT) | 2020-07-02 | — | — | US | claimed |
| EP-3658136-A1 | CFTR CHANNEL ACTIVATOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF GLUTEN SENSITIVITY CONDITIONS | Raia, Valeria (IT) | 2020-06-03 | — | — | EP | claimed |
| WO-2019020663-A1 | CFTR CHANNEL ACTIVATOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF GLUTEN SENSITIVITY CONDITIONS | MAIURI LUIGI (IT) | 2019-01-31 | — | — | WO | claimed |
| US-11988661-B2 | Rapid quantitative test to diagnose polycystic kidney disease | UMC UTRECHT HOLDING, B.V. (NL) | 2024-05-21 | — | — | US | disclosed |
| US-20210333266-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING, B.V. (NL) | 2021-10-28 | — | — | US | disclosed |
| US-20210333266-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING, B.V. (NL) | 2021-10-28 | — | — | US | disclosed |
| US-11035852-B2 | Identifying drug candidates for treating polycystic kidney disease using organoids generated from primary cells | UMC UTRECHT HOLDING, B.V. (NL) | 2021-06-15 | — | — | US | disclosed |
| US-20200206198-A1 | CFTR CHANNEL ACTIVATOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF GLUTEN SENSITIVITY CONDITIONS | MAIURI LUIGI (IT) | 2020-07-02 | — | — | US | disclosed |
| EP-3658136-A1 | CFTR CHANNEL ACTIVATOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF GLUTEN SENSITIVITY CONDITIONS | Raia, Valeria (IT) | 2020-06-03 | — | — | EP | disclosed |
| WO-2019020663-A1 | CFTR CHANNEL ACTIVATOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF GLUTEN SENSITIVITY CONDITIONS | MAIURI LUIGI (IT) | 2019-01-31 | — | — | WO | disclosed |
| EP-3045912-B1 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING BV (NL) | 2018-09-19 | — | — | EP | disclosed |
| EP-2795322-B1 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING BV (NL) | 2015-12-09 | — | — | EP | disclosed |
| US-20150276719-A2 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-10-01 | — | — | US | disclosed |
| US-20150276719-A2 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-10-01 | — | — | US | disclosed |
| US-20150276719-A2 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-10-01 | — | — | US | disclosed |
| WO-2015018831-A1 | LIGASE E3 RNF185 INHIBITORS AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-02-12 | — | — | WO | disclosed |
| EP-2835423-A1 | Ligase E3 RNF185 inhibitors and uses thereof | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2015-02-11 | — | — | EP | disclosed |
| US-20150011420-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-01-08 | — | — | US | disclosed |
| WO-2013093812-A2 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2013-06-27 | — | — | WO | disclosed |
| WO-2009105234-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH DEFECTS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE OR PROTEIN | COMBINATORX, INCORPORATED (US) | 2009-08-27 | — | — | WO | disclosed |